Award
National Cancer Institute 5R21CA293150-02
Immune Checkpoint Blockade Targeting the Novel PSGL-1/VISTA Axis for Pancreatic Cancer
Recipient
Not specified
Award Amount
$209,674.00
Ceiling
$209,674.00
Awarded
February 26, 2026
Identifier
5R21CA293150-02
Award for research on immunotherapy targeting PSGL-1/VISTA axis to treat pancreatic cancer, including preclinical studies and biomarker evaluation.
Description
This project focuses on developing immunotherapy targeting PSGL-1/VISTA axis for pancreatic cancer, with a focus on overcoming resistance to immune checkpoint blockade. The project involves preclinical studies using mouse models and aims to evaluate biomarkers for sensitivity to PSGL-1 targeting.